Press Releases
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
-
Fri, 19-Nov-2021
- Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
-
Tue, 16-Nov-2021
- Posted by: Biocon Biologics
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
-
Mon, 15-Nov-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
-
Thu, 04-Nov-2021
- Posted by: Biocon Biologics
Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
-
Fri, 22-Oct-2021
- Posted by: Biocon Biologics
Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
-
Thu, 21-Oct-2021
- Posted by: Biocon Biologics
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
-
Thu, 16-Sep-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
-
Thu, 29-Jul-2021
- Posted by: Biocon Biologics
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
-
Mon, 26-Jul-2021
- Posted by: Biocon Biologics
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
-
Fri, 23-Jul-2021
- Posted by: Biocon Biologics
